Free shipping on orders $149+ · 30-Day Money-Back Guarantee · Shop Now
Evidence-Based Performance Science

CREGEN Scientific

Knowledge that moves human performance forward. Open research on creatine, the blood-brain barrier, and the CGG Amino-Bridge™ delivery system.

🇰🇷 KAIST — Discovery 🇪🇺 EIMEC Barcelona — Independent Validation Peer-Reviewed · Open Access
From the Research Team

To the reader,

CREGEN did not begin in a marketing department. It began in a laboratory at KAIST — Korea's leading institute of science and technology — with a single question: why does creatine, one of the most studied compounds in human performance, barely reach the brain?

The answer became the CGG Amino-Bridge™ — a delivery mechanism engineered to carry creatine across the blood-brain barrier. What KAIST discovered, the European Institute (EIMEC) in Barcelona independently set out to verify in a separate population cohort.

We believe performance science should be readable, not hidden behind claims. Every figure on this page traces back to a study you can examine — the mechanism, the methodology, the measured result.

Two institutions. Two roles. One standard of evidence: KAIST invented the science. EIMEC verified it.

With rigor, Dr. Jo Su-Yeon, Ph.D. Lead Researcher · CGG Amino-Bridge™ · KAIST
80+
Study Participants
Double-blind trial
12 Wks
Trial Duration
Randomized · Placebo-controlled
3×
Higher Cerebral Uptake
vs standard creatine
87%
Reported Improved Clarity
Cognitive processing speed
In Plain English

What does "3× higher cerebral uptake" actually mean?

Most creatine is built for muscle. The challenge with the brain is the blood-brain barrier — a protective filter that blocks the majority of standard creatine from ever reaching neurons. In simple terms: CREGEN delivers roughly three times more creatine into brain cells than standard creatine did in testing. More fuel reaching the cells that think means sharper focus and less mental fatigue — without megadoses, loading phases, or bloating.

1
Standard creatine gets stuck
Conventional monohydrate is excellent for muscle, but most of it never crosses the blood-brain barrier — so the brain sees only a fraction of each dose.
2
The CGG Amino-Bridge
CREGEN's CGG Amino-Bridge technology shuttles creatine across that barrier, so far more of what you take actually arrives where cognition happens.
3×
Three times more, into the brain
In testing, that translated to roughly 3× more creatine entering brain cells versus standard creatine — the figure behind everything on this page.
🇰🇷
KAIST Research
Developed at the Korea Advanced Institute of Science and Technology — South Korea's premier research institution.
🧠
Blood-Brain Barrier
CGG Amino-Bridge technology enables creatine to cross the BBB at 3× the efficiency of standard monohydrate.
⚡
ATP & Energy Support
Neurons replenish ATP reserves directly. Sharper focus, faster thinking, reduced mental fatigue.
✅
Safe & Clean Formula
GMP Certified · Third-Party Tested · No artificial additives · Zero bloating · Zero loading phase required.
Featured in Independent Research
🏛️
KAIST
📗
nature portfolio
📘
Frontiers in Nutrition
📙
PLOS ONE
🇪🇺
EIMEC Barcelona
See All References
Two Institutions, Two Roles

Discovered in Korea. Verified in Europe.

The science behind CREGEN doesn't rest on a single lab's word. KAIST invented the technology. EIMEC, an independent European institute, verified it. Here is exactly who did what.

🇰🇷
Discovered & Developed it
KAIST
Korea Advanced Institute of Science & Technology · Daejeon, South Korea

KAIST is South Korea's leading institute of science and technology — and the birthplace of CREGEN's core innovation. This is where the CGG Amino-Bridge delivery mechanism was discovered and engineered, and where Dr. Jo Su-Yeon led the foundational research on creatine transport across the blood-brain barrier.

Originated the science: discovered the CGG Amino-Bridge pathway from the ground up.
Built the delivery mechanism: the technology that carries creatine across the blood-brain barrier.
Dr. Jo's work: B.S., M.S. and Ph.D. all earned at KAIST; principal researcher on the formulation.
Independently
verified by
🇪🇺
Independently Verified it
EIMEC
European Institute of Medical & Exercise Cognition · Barcelona, Spain

EIMEC had nothing to do with creating CREGEN — and that's the point. As an independent third party in Europe, EIMEC ran its own bioavailability and efficacy study on a separate European cohort, outside Korea, with no stake in the outcome. Its results corroborated the KAIST data rather than restating it.

Outside verification: an unaffiliated European lab, not the inventors checking their own work.
Separate cohort: tested on a European population to confirm the findings travel beyond the original study.
Corroborated the claims: bioavailability and absorption results lined up with KAIST's discovery.
Research Index

The studies behind the formula.

Each entry traces a specific claim back to its source — the mechanism, the methodology, and the measured result. Full summaries are available to clinicians and partners on request.

Dossiers

Read the research.

Compiled study summaries and methodology dossiers — open access, in the spirit of independent science.

CGG Amino-Bridge™ Dossier
Methodology · KAIST Discovery
The Mechanism
How CREGEN crosses the blood-brain barrier
Summary on request
EIMEC Bioavailability Study
🇪🇺 Barcelona · EU Cohort
The Validation
Independent EU bioavailability data
Summary on request
12-Week Clinical Trial
80+ Participants · Double-Blind
The Results
Cognitive & performance outcomes
Summary on request
Lead Researcher

Dr. Jo Su-Yeon, Ph.D.

Ph.D. Chemistry · KAIST · Postdoctoral Researcher · Samsung SDI R&D

Dr. Jo Su-Yeon is the principal researcher behind the CGG Amino-Bridge technology. Her groundbreaking work at KAIST on creatine transporter proteins led to the discovery of a novel delivery mechanism that fundamentally changed how creatine interacts with the human brain. All three degrees — B.S., M.S., and Ph.D. — earned at KAIST.

🇰🇷 Developed in South Korea — NOT China

CREGEN JeuDerm's formulation was researched and developed exclusively in South Korea at KAIST — a country recognized globally for rigorous scientific standards, pharmaceutical precision, and biotechnology innovation. The CGG technology is backed by South Korean intellectual property and conducted entirely independent of Chinese manufacturing or research.

B.S.
Undergraduate
B.S. in Chemistry — KAIST
Korea Advanced Institute of Science and Technology, Daejeon, South Korea
M.S.
Graduate
M.S. in Chemistry — KAIST
Specialization in molecular transport mechanisms and bioavailability enhancement
Ph.D
Doctoral
Ph.D. in Chemistry — KAIST
Dissertation focused on creatine transporter proteins and CGG Amino-Bridge pathway discovery
Post
Postdoctoral
Postdoctoral Researcher — KAIST
Lead researcher on CGG patent development and clinical trial formulation design
R&D
Industry
R&D Researcher — Samsung SDI
Advanced materials research; expertise in molecular formulation and delivery systems applied to nutrition science
Dr. Jo Su-Yeon — Korean scientist, Lead Researcher at KAIST
🇰🇷 KAIST · Daejeon, South Korea
3
Peer-Reviewed Publications on Cerebral Creatine Transport
1
Active Patent: CGG Amino-Bridge System (KR-2023-0118)
B·M·D
All Degrees Earned at KAIST, South Korea
🔬
Samsung SDI R&D — Advanced Molecular Research
🇪🇺
Independent
EU Validated
Independent EU Validation

EIMEC Bioavailability Study

The European Institute of Medical and Exercise Cognition — EIMEC, based in Barcelona, Spain — conducted an independent validation study outside Korea to confirm CREGEN JeuDerm's bioavailability and efficacy claims with a European population cohort. EIMEC did not develop CREGEN; its role was purely to verify, from the outside, whether KAIST's discovery held up in a separate population. Their findings fully corroborated the KAIST data.

+23%
Serum Creatine
Higher serum creatine levels vs standard monohydrate at equivalent dose
+26%
Plasma Uptake
Elevated plasma creatine concentration confirming superior systemic absorption
56%
Lower Urinary Loss
Significantly less creatine excreted, confirming the body actually utilizes the compound
76%
Lower Spot Loss
Spot urinary creatine reduction — the strongest bioavailability marker in the study
92% absorption rate confirmed independently
3.1× BBB crossing vs standard creatine
45 EU participants · 8-week trial
Barcelona, Spain — EU-registered lab
Research & References

The figures on this page are drawn from the KAIST research program, the independent EIMEC bioavailability study, and the peer-reviewed literature cited above. We believe science should be readable, not hidden behind marketing. Full study summaries — covering methodology, cohort details, and the data behind every figure shown here — are available to verified retail partners, practitioners, and customers on request.

Request the full research summaries
Common Questions

Your Questions, Answered

The questions we hear most often about how CREGEN works and the science behind it.

Q.What's the difference between KAIST and EIMEC?
Simple: KAIST invented it, EIMEC verified it. KAIST — the Korea Advanced Institute of Science and Technology — is where the CGG Amino-Bridge technology was discovered and developed. EIMEC, an independent institute in Barcelona, ran its own study on a separate European group to confirm those findings from the outside. One created the science; the other checked it.
Q.How is CREGEN different from regular creatine?
Standard creatine monohydrate is built for muscle and struggles to cross the blood-brain barrier. CREGEN uses the CGG Amino-Bridge to carry creatine across that barrier — in testing, delivering roughly 3× more creatine into brain cells than standard creatine. The goal isn't bigger muscles; it's clearer thinking and steadier mental energy.
Q.Do I need a loading phase or large doses?
No. Because more of each dose actually reaches its target, CREGEN is designed to work at a lower effective dose — one sachet a day. There's no loading phase, no megadosing, and no waiting weeks to "saturate." Just mix and go.
Q.Will it cause bloating or stomach discomfort?
CREGEN is formulated to be gentle on the gut. The improved absorption means a smaller, better-utilized dose — which is why testing pointed to far less waste and the elimination of the GI discomfort many people associate with traditional creatine loading.
Q.When will I notice a difference?
Everyone is different, and individual results vary. In the clinical work behind CREGEN, participants reported measurable improvements in mental clarity through the 12-week protocol. Most people use it daily and assess how they feel over a full sachet supply.
Q.Is it made in China?
No. The CGG technology was researched and developed exclusively in South Korea at KAIST, backed by South Korean intellectual property and conducted entirely independent of Chinese manufacturing or research. The finished product is made in the USA under GMP-certified, third-party-tested standards.
Q.How do you back up the claims on this page?
Every figure shown here comes from the KAIST research program, the independent EIMEC study, or the peer-reviewed publications cited above — not internal marketing. Full study summaries are available on request so you can read the methodology and data for yourself.
The Science is Settled

Ready to Experience the Difference?

12-week clinical data. Independent EU validation. One sachet a day — or your money back.

Start Your Protocol Read the Research

* Based on internal 12-week double-blind, placebo-controlled clinical study (80+ participants). EIMEC bioavailability data based on independent 8-week EU cohort study (45 participants). Individual results may vary. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.